Published:
National Coalition for Quality Colorectal Cancer Screening and Care Testifies Before FDA Advisory Panel on Fospropofol Labeling:
National Coalition for Quality Colorectal Cancer Screening and Care Testifies Before FDA Advisory Panel on Fospropofol Labeling:
ANNAPOLIS, Md., May 16 /PRNewswire/ -- Dr. Stanford Plavin, Board Vice
Chairperson of the National Coalition for Quality Colorectal Cancer Screening
and Care ("Coalition"), a 501(c) 6 not-for-profit association, testified on
May 7th before the U.S. Food and Drug Administration (FDA) Anesthetic and Life
Support Drugs Advisory Committee relating to the importance of patient safety
when anesthetic agents are administered during colonoscopy screenings.
"I am extremely pleased that the FDA Advisory Committee chose to consider
patient access and safety first and foremost in their analysis of fospropofol
and how it should be administered," said Dr. Plavin, managing partner of
Ambulatory Anesthesia ofAtlanta, P.C. "While the recommendations of the FDA
Advisory Committee are not binding, it speaks for itself that the Committee
members voted nine to one to restrict the use of fospropofol. This agent
should be administered only by persons trained in the administration of
general anesthesia and not involved in the conduct of the surgical/diagnostic
procedure. The practitioner administering fospropofol for sedation/anesthesia
should have the education and training to identify and manage the airway and
cardiovascular changes which occur in a patient who enters a state of general
anesthesia, as well as the ability to assist in the management of
complications."
"A primary goal of the Coalition is to promote safe sedation for
colorectal cancer screening," notes Steven J. Morris, MD JD FACP FACG,
Coalition Board Chairperson and CEO of Atlanta Gastroenterology Associates,
LLC. "The Coalition is dedicated to ensure that patient care and quality is
never compromised. Minimizing appropriate clinical oversight in an attempt to
save dollars, at the expense of patient safety or at the cost of human lives,
is unacceptable."
The Coalition, comprised of gastroenterologists, surgeons, primary care
physicians, oncologists, anesthesiologists, patient advocacy groups, and
concerned individuals, supports a sustained effort of advocacy, collaboration,
research, and education geared toward key stakeholders, including the public.
Dr. Morris notes, "Access to optimal agents for sedation delivered by
appropriately trained professionals is critical in order to encourage patients
to undergo screening colonoscopies. We applaud the recommendations of the FDA
Advisory Committee and look forward to their formal adoption by the FDA."
To learn more about the activities of the Coalition, visit
http://www.preventingcolorectalcancer.org. You can contact the Coalition at
(866) 461-9296 (toll free) or via email to
info@preventingcolorectalcancer.org.
Headquartered inAnnapolis, Maryland, the National Coalition for Quality
Colorectal Cancer Screening & Care (http://www.preventingcolorectalcancer.org)
has been established to preserve the tradition of safe, comfortable and
quality-based medicine. The mission of the Coalition is to educate the public
and key stakeholders about the opportunities to reduce the incidence of
colorectal cancer through maintaining screening and care options for patients.
SOURCE National Coalition for Quality Colorectal Cancer Screening & Care
Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze,
Daily NewsTags: Healthcare, Pharmaceuticals, Health, , maryland
_ _Is your favorite bookmark site missing?
Ask for it.
Search News
Daily News
